PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Euronext Amsterdam
|
||
| - EUR | - |
|
| 09-14 | Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja | MT |
| 09-12 | Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S | CI |
| Market Cap | 744M 649M 613M 556M 1.04B 71.4B 1.05B 7.34B 2.83B 36.3B 2.8B 2.73B 117B | P/E 2026 * |
33.7x | P/E 2027 * | 25x |
|---|---|---|---|---|---|
| Enterprise Value | 697M 608M 574M 521M 977M 66.92B 981M 6.88B 2.65B 34.03B 2.62B 2.56B 109B | EV / Sales 2026 * |
1.82x | EV / Sales 2027 * | 1.63x |
| Free-Float |
98.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 04/03/2025 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 01/10/2025 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/06/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 11/12/2020 |
Mark Pykett
BRD | Director/Board Member | 62 | 11/12/2020 |
| Director/Board Member | 60 | 19/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | +0.20% | +3.26% | +26.15% | +45.30% | 400.19B | |
| Weighted average by Cap. | +0.23% | +3.09% | +35.15% | +61.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 383M 334M 316M 287M 537M 36.78B 539M 3.78B 1.46B 18.7B 1.44B 1.41B 60.17B | 417M 364M 344M 312M 585M 40.04B 587M 4.12B 1.59B 20.36B 1.57B 1.53B 65.5B |
| Net income | 22.11M 19.28M 18.21M 16.53M 30.97M 2.12B 31.1M 218M 84.15M 1.08B 83.06M 81.22M 3.47B | 33.62M 29.32M 27.68M 25.14M 47.1M 3.23B 47.29M 332M 128M 1.64B 126M 123M 5.28B |
| Net Debt | -46.69M -40.71M -38.44M -34.91M -65.41M -4.48B -65.68M -461M -178M -2.28B -175M -172M -7.33B | -62.12M -54.17M -51.14M -46.44M -87.02M -5.96B -87.38M -613M -236M -3.03B -233M -228M -9.75B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
